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Despite the well-known beneficial ef-fects of statins, adherence to statin
treatment is poor in daily medical prac-
tice. One-year persistence with statins
has been estimated to be about 60% in
patients with previous cardiovascular
events1-3; in primary prevention, discon-
tinuation rates are likely to be even high-
er.3,4 Poor adherence is a major barrier to
successful treatment. Therefore, poten-
tial benefits of statins as established in
randomized controlled trials may not be
accomplished in clinical practice. Both
the World Health Organization and the
European Council have advocated for a
multidisciplinary approach in addressing
nonadherence. In this approach, the
community pharmacist has an important
role to play in ensuring that drug therapy
is appropriate and the patient has an opti-
mal chance of success with therapy.5,6
Community-based pharmacists are the
most easily accessible health-care
providers, have extensive knowledge
about drug therapy and disease manage-
ment, and can provide information and
education to the patient and monitor ad-
herence. 
Several randomized controlled trials
have been conducted in which pharma-
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BACKGROUND: Despite the well-known beneficial effects of statins, many patients
do not adhere to chronic medication regimens.
OBJECTIVE: To implement and assess the effectiveness of a community phar-
macy–based pharmaceutical care program developed to improve patients’ ad-
herence to statin therapy.
METHODS: An open-label, prospective, randomized controlled trial was conducted at
26 community pharmacies in the Netherlands. New users of statins who were aged
18 years or older were randomly assigned to receive either usual care or a
pharmacist intervention. The intervention consisted of 5 individual counseling ses-
sions by a pharmacist during a 1-year period. During these sessions, patients
received structured education about the importance of medication adherence, lipid
levels were measured, and the association between adherence and lipid levels was
discussed. Adherence to statin therapy was assessed as discontinuation rates 6
and 12 months after statin initiation, and as the medication possession ratio (MPR),
and compared between the pharmaceutical care and usual care groups. 
RESULTS: A total of 899 subjects (439 in the pharmaceutical care group and 460 in
the usual care group) were evaluable for effectiveness analysis. The pharmaceutical
care program resulted in a significantly lower rate of discontinuation within 6 months
after initiating therapy versus usual care (HR 0.66, 95% CI 0.46 to 0.96). No signi-
ficant difference between groups was found in discontinuation at 12 months (HR
0.84, 95% CI 0.65 to 1.10). Median MPR was very high (>99%) in both groups and
did not differ between groups.
CONCLUSIONS: These results demonstrate the feasibility and effectiveness of a
community pharmacy–based pharmaceutical care program to improve medication
adherence in new users of statins. Frequent counseling sessions (every 3 months)
are necessary to maintain the positive effects on discontinuation. Although
improvements are modest, the program can be applied easily to a larger population
and have a large impact, as the interventions are relatively inexpensive and easy to
implement in clinical practice.
KEY WORDS: adherence, cardiovascular drugs, lipids, pharmaceutical care. 
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ceutical interventions to enhance medication adherence
have been implemented.7-17 Evaluated interventions range
from giving patients more information and education on
the goals and benefits of drug therapy to the simplification
of the drug regimen and intensification of patient care by
telephone reminders, home visits, and follow-up inter-
views. Most randomized controlled trials showed benefi-
cial effects on adherence,10,15,17 lipid levels,7,8,13,14,16 or both.9
Moreover, overall health-care expenditures in the interven-
tion and control groups seem to be similar, despite in-
creased visits to the pharmacist and laboratory costs.8
It has been shown that the most critical need for adher-
ence interventions is during the first few months of thera-
py, as adherence levels drop shortly after initiation of statin
treatment.18 Hence, persons who have been newly pre-
scribed medications comprise an interesting subgroup when
pharmaceutical care programs are implemented. Most stud-
ies aimed at improving adherence among users of statins
were hospital pharmacy–based,7-10,14,16 sometimes with com-
plex interventions10,14,17 and mostly not focusing solely on
patients initiating statin treatment.7,8,10-14,16 We therefore de-
veloped a large multicenter community pharmacy–based
pharmaceutical care program for new statin users. This pro-
gram was aimed at improving adherence to statin therapy
by giving patients education and feedback on achieved lipid
levels. These interventions are easy to implement in com-
munity pharmacies, are relatively inexpensive, and have
been shown to be effective in clinical trials with various pa-
tient populations.13,14 The purpose of our study was to ex-
amine the feasibility and effectiveness of this program. 
Methods
STUDY POPULATION
Our study, the STIPT (STatin Intervention research Pro-
jecT), was a community pharmacy–based, multicenter,
open-label, randomized controlled trial to improve medica-
tion adherence in new users of statins. Patients were re-
cruited from 26 community pharmacies (both independent
and chain stores) in the Netherlands and were eligible for
inclusion if they were new users of statins, were aged 18
years or older, and were capable of visiting the pharmacy.
New users were defined as those who had not filled a pre-
scription for statins in the preceding 6 months, verified by
the pharmacist through a patient record check. Virtually all
Dutch inhabitants are registered with a single community
pharmacy, independent of prescriber; consequently, phar-
macy records are nearly complete with regard to prescrip-
tion drugs.19 The study was approved by the Medical Com-
mittee of Ethics of the University Medical Centre Utrecht
and all patients signed informed consent forms prior to the
study. Study enrollment started in September 2004 and
was completed in March 2006. 
STUDY DESIGN
Once the informed consent form was received, each
participant was randomly assigned to either the intervention
or control group by a procedure that was built into the com-
puter system and used a set of random numbers in a 1:1 ratio.
Patients in the intervention (pharmaceutical care) group were
invited to visit the pharmacy for 5 individual counseling vis-
its, each lasting 10-15 minutes. Counseling visits were sched-
uled at first prescription, at second prescription (after 15
days), and at subsequent refill dates at 3, 6, and 12 months af-
ter the start of statin therapy. In the Netherlands, the first pre-
scription for statins is limited to 15 days20 and subsequent
prescriptions are generally dispensed in 3-month supplies.
Because it has been shown that patients are most likely to dis-
continue statins in the first months after therapy initiation,18
counseling sessions were scheduled more frequently during
the first months of treatment. Counseling at time of first pre-
scription comprised structured education on indication, ef-
fects, and adverse effects of statin therapy; dosage; impor-
tance of medication adherence; and intended duration of
treatment. Additionally, a drug information letter that sum-
marized the verbal information was given to each patient. At
the time of the second prescription, patients were asked about
their experience with statin therapy, potential drug-related
problems, and difficulties in adhering to the dosing regimen.
At 3, 6, and 12 months, total cholesterol, high-density
lipoprotein cholesterol, and triglyceride levels were measured
from fasting fingerstick whole blood samples using
Cholestech LDX Analyzers (Cholestech Corp., Hayward,
CA) and low-density lipoprotein cholesterol (LDL-C) was
estimated by the Friedewald formula.21 Measured lipid levels
and treatment goals were recorded on a wallet card that was
kept by all patients to monitor their progress in lowering lipid
levels. In addition, medication adherence was assessed via
unused pill counts, and the association between adherence
and lipid levels was discussed to encourage patients to adhere
to the prescribed dosing regimen.
Patients in the control group were provided usual care,
consisting of verbal and written drug information accord-
ing to the standard protocol in the pharmacies. Patients in
the usual care group did not receive lipid measurements or
counseling sessions. 
In both the pharmaceutical care and usual care groups,
patients were asked to fill out a questionnaire at baseline
and after 6 and 12 months. The baseline questionnaire in-
cluded items on sociodemographics, family history of car-
diovascular disease (CVD), comorbidities, self-perceived
health, lifestyle factors (smoking habits, alcohol consump-
tion, dietary habits), and the application of other lipid-low-
ering strategies (eg, eating healthier or becoming more
physically active). Questionnaires at 6 and 12 months con-
tained questions about changes in self-perceived health and
lifestyle modifications to lower lipid levels. 
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All questions about the study or treatment from patients
in both treatment arms were answered as forthrightly as
possible. Participants and those administering the interven-
tions were not blinded to the treatment assignment. Con-
versely, those assessing differences in outcomes between
the pharmaceutical care and usual care groups remained
blinded throughout the study. 
OUTCOME DEFINITION
Electronic pharmacy dispensing records of all patients
were collected at the end of follow-up. Adherence to
statins was evaluated in terms of discontinuation of treat-
ment and the medication possession ratio (MPR).22 The
primary endpoint of this study was discontinuation of treat-
ment assessed 1 year after the start of statin therapy. Sec-
ondary endpoints were discontinuation rates 6 months after
statin initiation, the MPR, and the relation between MPR and
total cholesterol and LDL-C levels. Patients were considered
to have discontinued therapy if they failed to refill their statin
agents within 90 days or 1 time the theoretical duration of the
prescription, whichever was the lowest number of days.23
Time to discontinuation was defined as the number of days
between the start of statin therapy and the discontinuation
day. When a patient refilled a prescription for the same type
of statin before the theoretical end date of the previous pre-
scription, we assumed that the new prescription began after
the end date of the previous one.24 Patients who switched
from one type of statin to another were considered to be con-
tinuous users. Patients were censored at the end of the study
period or when they changed to a pharmacy not participating
in the study or died before the end of follow-up. The patient’s
MPR was assessed from the pharmacy dispensing records at
the end of the study or, for patients who stopped statin thera-
py earlier, at the time of discontinuation. The MPR was cal-
culated as the ratio of the sum of the days’ supply of all statin
medication dispensed divided by the length of therapy. A pa-
tient with an MPR of 0.9 or more was defined as being ad-
herent to the prescribed dosing regimen. Medication adher-
ence assessed by pill counts during the counseling sessions
was not regarded as an outcome of this study but was used
solely to instantly address  an individual’s adherence at the
counseling session.
STATISTICAL ANALYSIS
Necessary sample size was estimated with the assumption
of a 1-year discontinuation rate of 33% in the control group,
as suggested by a previous study in a comparable patient
population,25 and of 24% in the pharmaceutical care group.
The pharmaceutical care discontinuation rate was chosen
conservatively based on previous effects of community phar-
macy–based programs.15,17 With an 80% power of detecting a
significant difference (p = 0.05, 2-sided) between the 2
groups and an expected loss to follow-up of 20%, a sample
size of 493 patients in each group (986 total) was required. 
Patient characteristics were compared between the phar-
maceutical care and usual care groups using an indepen-
dent sample Student’s t-test or χ2 test as appropriate. Dis-
continuation was estimated by using Kaplan-Meier analy-
sis and was compared between the groups with a log-rank
test. Univariate Cox proportional hazard models were used
to compare further the probability of discontinuation be-
tween the groups. In addition, Cox proportional hazard
models were used to estimate the probability of discontinu-
ation at 12 months in various exploratory subgroups that
were defined by factors potentially associated with discon-
tinuation. Those factors were age, sex, level of education,
comorbidities (hypertension, diabetes, history of CVD), fa-
milial hypercholesterolemia, the application of other lipid-
lowering strategies, and the number of medications used
(at Anatomical Therapeutic Chemical [ATC] classification
level 3).26 A treatment-by-subgroup interaction term was
added to the model to test whether different subgroups had
different risks. The MPR between the 2 study groups was
analyzed using the nonparametric Mann-Whitney U test
and the percentage of subjects having a high (≥90%) or
low (<90%) MPR was compared using the χ2 test. The
number of subjects switching to a statin with a different
equipotency score (measure for the potency of a statin to
lower total cholesterol according to type and dose)27 was
computed and compared between the pharmaceutical care
and usual care groups with the Mann-Whitney U test. 
Lipid levels were measured only in the intervention
group as part of the pharmaceutical care program; there-
fore, the effect of differences in MPR on lipid levels could
be estimated only in these subjects. Patients were consid-
ered to have met lipid treatment goals if they achieved fast-
ing total cholesterol levels of <190 mg/dL and LDL-C lev-
els of <115 mg/dL.28,29 The percentage of subjects reaching
lipid goals among patients with a high (≥90%) or low
(<90%) MPR was compared using the χ2 test. Spearman
correlation was used to determine the relationship between
the MPR and lipid levels. 
The results were considered statistically significant at a 2-
sided probability level of p < 0.05. All statistical analyses
were performed according to the intention-to-treat principle
using SAS version 9.1.3 (SAS Institute, Cary, NC). 
Results 
PATIENT ENROLLMENT AND BASELINE CHARACTERISTICS 
A total of 1016 subjects were enrolled in the trial, 513
(50%) of whom were randomized to the pharmaceutical
care group and 503 (50%) to the usual care group (Figure
1). A total of 117 patients were excluded because no phar-
macy dispensing data were available for these subjects,
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due to mismatch between data from the electronic records
and the handwritten study entry forms. Thus, 899 patients
(439 in the pharmaceutical care group and 460 in the usual
care group) were eligible for analysis. Of the patients in the
pharmaceutical care group, 62 (14%) did not attend any
follow-up counseling session, whereas 29 (7%), 43 (10%),
and 305 (69%) patients attended 3, 4, and all 5 counseling
sessions, respectively. 
Baseline characteristics of the patients are shown in
Table 1. Mean age of all participants was 60.1 ± 11.1 years
and 49% were male. Most patient characteristics were sim-
ilar between the groups. However, significantly more pa-
tients in the usual care group had a history of CVD, and
those in the usual care group classified their health status
more often as moderate/poor. Significantly more patients
in the pharmaceutical care group were prescribed atorva-
statin, whereas fewer pharmaceutical care patients were
prescribed rosuvastatin. A substantial number of patients
(52%) started statin therapy at a medium equipotency
score, equivalent to a simvastatin dose of 20 mg/day or an
atorvastatin dose of 10 mg/day.
DISCONTINUATION OF STATIN TREATMENT 
Figure 2 presents the Kaplan-Meier curve, comparing
discontinuation of statin therapy over time between patients
in the pharmaceutical care and usual care groups. Of the 899
patients, 58 were censored (20 in the pharmaceutical care
group and 38 in the usual care group) because they died or
left the study pharmacy before the end of follow-up. A total
of 47 (11%) patients in the pharmaceutical care group and 72
(16%) patients in the usual care group discontinued statins
within 6 months after the initiation of treatment (p value for
log-rank test = 0.026). The corresponding percentages at 1
year after the start of therapy were 23% and 26%, respective-
ly, in the pharmaceutical care and usual care groups (p value
for log-rank test = 0.21). The hazard rate ratio of discontinu-
ing statin therapy, as determined by the Cox proportional
hazard analysis, showed that patients in the pharmaceutical
care group had a statistically significantly lower rate of dis-
continuation within 6 months after initiating therapy than did
patients in the usual care group (HR 0.66, 95% CI 0.46 to
0.96). Thus, patients in the pharmaceutical care group were
34% less likely to discontinue treatment, or 1.52 (95% CI
1.04 to 2.17) times more likely to persist with treatment com-
pared to patients in the usual care group. Twelve months after
therapy was initiated, this difference in discontinuation rate
was not statistically significant (HR 0.84, 95% CI 0.65 to
1.10). 
Analyses of discontinuation rates by subgroups are shown
in Figure 3. We noted a significant treatment-by-subgroup in-
teraction between patients using ≤5 or >5 medications at the
ATC3-level (treatment-by-subgroup interaction, p = 0.028),
which indicated that patients using more medications were
less likely to benefit from the pharmaceutical care program.
Although patients aged 50 years or younger, females, the
higher educated, and patients who did not implement other
lipid-lowering strategies seemed to gain more benefit from
receiving pharmaceutical care, the differences in effect of the
pharmaceutical care program between the subgroups were
not statistically significant. 
MEDICATION POSSESSION RATIO AND STATIN
ADJUSTMENTS
The median MPR (25th-75th percentile) was 99.5%
(96.9-100%) in the pharmaceutical care group and 99.2%
(95.6-100%) in the usual care group (p = 0.14). Only 37
patients (8%) in the pharmaceutical care group and 54 pa-
tients (12%) in the usual care group had an MPR <90%
(χ2; p = 0.10). There was no significant difference between
the groups in the percentage of patients switching to a
statin with a different equipotency score. 
LIPID LEVELS
In patients receiving pharmaceutical care, both mean to-
tal cholesterol and LDL-C levels declined significantly
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Figure 1. Patient enrollment.
during the study. The average reduction in total cholesterol
and LDL-C was 17.2 mg/dL (95% CI 12.3 to 22.0) and
9.47 mg/dL (95% CI 5.02 to 13.9), respectively. Three
months after initiating statin therapy, 65% of these subjects
reached the target LDL-C level of below 115 mg/dL. At 6
and 12 months after treatment, these percentages were
72% and 77%, respectively. A higher percentage of adher-
ent patients (MPR ≥90%) than nonadherent patients
reached target LDL-C levels after 3 months (67% vs 45%,
respectively; p = 0.01) and 6 months (74% vs 50%, respec-
tively; p = 0.01). Spearman’s correlation showed a signifi-
cant negative association between the MPR and total
cholesterol (r = –0.16; p = 0.002) and a trend toward a
negative association between the MPR and LDL-C level (r
= –0.10; p = 0.08). 
Discussion
Patients who understand the benefits of treatment and
are satisfied with health-care provider communication, and
those with frequent follow-up lipid tests, have been shown
to be more adherent to statin therapy.30 In our study, a com-
munity pharmacy–based pharmaceutical care program
composed of patient counseling and feedback on achieved
lipid levels was associated with modestly lower discontin-
uation rates of statin therapy. Compared to patients in the
usual care group, those in the pharmaceutical care group
were 34% less likely to discontinue treatment within 6
months (p = 0.03) and 16% less likely to discontinue treat-
ment within 1 year after initiating statin therapy (p = NS).
This difference in effect on discontinuation rates between 6
and 12 months might imply that frequent counseling sessions
(every 3 months) are necessary to maintain the positive ef-
fects. However, the fact that the difference between groups in
discontinuation rates at 12 months did not reach statistical
significance could also be explained by other factors. Most
importantly, discontinuation rates in the usual care group
were lower than anticipated. The margin for improvement
was therefore less than that hypothesized in the power calcu-
lation. This might be due to the fact that adherent patients and
pharmacies that had already been involved in advanced pro-
vision of pharmaceutical care were more willing to partici-
pate in the program. Moreover, adherence to therapy in the
usual care group might have been enhanced because the sub-
jects were aware that their behavior was being monitored.
Several studies aimed at improving adherence have shown
unexpected high adherence in usual care groups.31,32 The fact
that patients included in the study reported a relatively high
proportion of health-promoting behavior modifications sug-
gests that study patients were more aware of their lipid levels
and cardiovascular risk. Therefore, the effect of this pharma-
ceutical care program on adherence might be higher in rou-
tine medical practice. 
Another reason for the lack of effect of the pharmaceuti-
cal care program on 1-year discontinuation rates is that
19% and 31% of the patients randomized to the pharma-
ceutical care group did not attend the follow-up counseling
session at 6 and 12 months, respectively. Patients not ad-
hering to the study protocol cannot benefit optimally from
the program, leading to a diluted treatment effect. When
this program is being implemented in daily medical practice,
A Pharmaceutical Care Program to Improve Adherence to Statin Therapy
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Table 1. Baseline Patient Characteristics in the
Pharmaceutical Care and Usual Care Groups 
Pharmaceutical Usual
Characteristic Carea Careb
Age, y (mean ± SD) 60.2 ± 10.9 60.1 ± 11.3
Male, n (%) 207 (47) 230 (50)
Dutch origin, n (%)c 359 (91) 380 (93)
Marital status, n (%)c
married/living together 297 (80) 325 (83)
unmarried/widowed/divorced 74 (20) 67 (17)
Level of education, n (%)c,d
low 156 (42) 162 (42)
intermediate 160 (43) 158 (40)
high 53 (14) 70 (18)
Comorbidities, n (%)c
hypertension 169 (43) 200 (49)
diabetes mellitus 115 (29) 111 (27)
respiratory disease 30 (8) 35 (9)
History of CVD, n (%)c,e 117 (30) 146 (37)
Family history of 96 (24) 112 (27)
hypercholesterolemia, n (%)c
Lifestyle factors, n (%)c
current smoker 93 (24) 88 (22)
alcohol use ≥1 time/wk 73 (20) 68 (17)
following a specific diet 155 (40) 160 (40)
Other lipid-lowering strategies, n (%)c
smoking cessation or reduction 53 (14) 42 (10)
reducing alcohol consumption 52 (13) 50 (12)
eating healthier 184 (47) 199 (49)
becoming more physically active 148 (38) 169 (42)
using plant sterol/stanols 154 (39) 166 (41)
Self-perceived health, n (%)c,e
(very) good 276 (74) 273 (69)
moderate/poor 96 (26) 125 (31)
Statin, n (%)d
simvastatin 157 (36) 153 (33)
pravastatin 40 (9) 59 (13)
atorvastatine 169 (39) 139 (30)
rosuvastatine 68 (15) 98 (21)
fluvastatin 4 (1) 11 (2)
CVD = cardiovascular disease.
aN = 439.
bN = 460.
cNumbers vary due to missing responses in the questionnaire. Per-
centages are calculated without missing values. 
dDue to rounding, percentages may not total 100%.
eStatistically significant difference, p < 0.05, χ2 test.
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Figure 3. Incidence of discontinuation of statin agents in subgroups of the STatin Intervention research ProjecT according to Cox proportional hazard
analyses. ATC3-level = Anatomical Therapeutic Chemical classification level 3; CVD = cardiovascular disease; HC = hypercholesterolemia.
Figure 2. Kaplan-Meier curve for discontinuation of statin agents in patients in the pharmaceutical care group and in the usual care group (n = 899). 
an effort should be made (eg, by sending reminders and con-
tacting patients who did not show up for their scheduled
counseling session) to ensure that patients adhere to the coun-
seling sessions. In our study, we present only results obtained
from an intention-to-treat analysis. Analyzing results accord-
ing to the per protocol principle of including only patients
who had at least 1 follow-up counseling visit could introduce
selection bias33 due to associations between discontinuation
of statin therapy and study dropout. 
Finally, significantly more patients in the usual care
group reported a history of CVD. This might have affected
our results, as it is known that persistence with statin thera-
py is better among patients with preexisting CVD.34 How-
ever, including CVD status as a confounder in Cox propor-
tional hazard analysis did not change our results. 
Although not statistically significant, the pharmaceutical
care program seemed to be more effective in younger pa-
tients, females, the higher educated, and patients not taking
many other medications (ie, patients generally classified as
having a lower cardiovascular risk profile). Several obser-
vational studies have shown lower statin adherence among
these patients.35-38 Therefore, the margin of improvement
might be greater in these subgroups. 
Despite the high MPR, we found significant associations
between differences in the MPR and total cholesterol– and
LDL-C–lowering effects. Because lipid levels were mea-
sured only in the pharmaceutical care group, we were not
able to study the effects of the pharmaceutical care interven-
tion on lipid levels. Measuring lipid values in the usual care
group probably would have influenced patients’ behavior and
thereby would have increased adherence in the usual care
group. As a result, the effect of the intervention would have
been diluted. However, as discussed earlier, it is still conceiv-
able that adherence to therapy is higher in the usual care
group compared to daily medical practice. 
We did not observe more patients switching to another
type or dose of statin in the pharmaceutical care group. Ap-
parently, measuring lipid levels can be seen primarily as a
method to give feedback to patients on the effect of statin
treatment and does not result in adjustments of drug therapy.
However, a lack of feedback from the pharmacist to the
physician might also be a reason for the absence of dosage or
drug adjustments. 
In our study we used pharmacy dispensing data to cal-
culate patient adherence to statin medication. These data
present many advantages over self-reported adherence and
medical records. Dispensing data are not suspect to patient-
related recall bias and reduce nonresponse bias. However,
uncertainty still exists as to whether dispensed drugs are
actually being taken according to the prescribed regimen.
In a study monitoring patient adherence to lipid-lowering
therapy in clinical practice, it was found that, during the
monitoring period of 6 months, approximately 60% of pa-
tients erroneously took multiple doses of statins per day.39
In addition, we did not have information for many patients
about the reason for discontinuation, and therefore we
were unable to assess whether statin therapy was discontin-
ued for clinical reasons. However, this would seem uncom-
mon, as statin therapy is mostly indicated over a patient’s
lifetime and statins have a relatively mild adverse event
profile.40 Another limitation of our study is that we could
not perform a double-blind study because of the nature of
the intervention studied in this trial. 
We recognize that randomization at the patient level,
rather than at the pharmacy level, may have contaminated
the care received by the patients in the usual care group by
pharmacists’ knowledge of the pharmaceutical care program.
This would have increased the risk of a type II error (ie, in-
correctly accepting the null hypothesis) and therefore could
have diluted the effect size. In our study, however, extra time
was scheduled for patients in the pharmaceutical care group
for measuring the lipid levels and for counseling. Patients
randomized to the usual care group visited the pharmacy
only to refill their statin prescription. The alternative of a
cluster-randomized trial would have given rise to other prob-
lems, such as recruitment bias, since participants are recruited
after the clusters have been randomized.41-43
In conclusion, we demonstrated the feasibility and effec-
tiveness of a community pharmacy–based pharmaceutical
care program to improve medication adherence in new users
of statins. Although improvements in adherence were mod-
est, the program is convenient for the patients because coun-
seling sessions are linked to the prescription refill dates.
Moreover, the interventions are relatively inexpensive and
easy to implement; the lipid tests cost about $80 per patient
and counseling sessions take an additional hour per patient.
Therefore, the program can be applied easily to a larger popu-
lation and have a large impact on population level. Health
economic studies should be performed to fully assess the
cost-effectiveness of this pharmaceutical care program. 
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Programa de Cuidado Farmacéutico Para Mejorar la Adherencia a la
Terapia de Estatina: Estudio Aleatorio Controlado
SRBM Eussen, ME van der Elst, OH Klungel, CJM Rompelberg, J Garssen,
MH Oosterveld, A de Boer, JJ de Gier, y ML Bouvy
Ann Pharmacother 2010;44:1905-13.
EXTRACTO
TRASFONDO: A pesar de los efectos beneficiosos conocidos de las estatinas,
muchos pacientes no se adhieren a los regímenes de medicación crónica. 
OBJETIVO: Implementar y evaluar la eficacia de un programa de cuidado
farmacéutico en la farmacia de comunidad desarrollado para mejorar la
adherencia del paciente a la terapia con estatinas. 
METODOLOGÍA: Estudio abierto, prospectivo, aleatorizado, y controlado
se realizó en 26 farmacias de comunidad en los Países Bajos. Los
nuevos pacientes de las estatinas con 18 años o más fueron asignados
aleatoriamente para recibir la atención habitual o una intervención
farmacéutica. La intervención consistió en 5 sesiones de consejería
individual por un farmacéutico durante un período de 1 año. Durante
estas sesiones, los pacientes recibieron educación estructurada sobre la
importancia de la adherencia a los medicamentos. Los niveles de lípidos
fueron medidos y la asociación entre los niveles de adherencia y los
niveles de lípidos fueron discutido. La adherencia a la terapia con estatinas
se evaluó con las tasas de descontinuación en 6 y 12 meses después del
inicio de las estatinas y la relación de posesión de medicamentos (MPR). 
RESULTADOS: Un total de 899 sujetos (439 en el grupo de cuidado farma-
céutico y 460 en el grupo de cuidado habitual) fueron evaluados para el
análisis de la eficacia. El programa de cuidado farmacéutico  resultó en
una una tasa significativamente menor en la descontinuación dentro de
los 6 meses después de iniciar el tratamiento (HR 0.66, CI 95% 0.46-
0.96). No hubo diferencia significativa entre los grupos en la descon-
tinuación en los 12 meses (HR 0.84, CI 95% 0.65-1.10). MPR fue muy
alto (>99%) en ambos grupos y  no hubo diferencia entre los grupos. 
CONCLUSIONES: Se demostró la viabilidad y eficacia de un programa de
cuidado farmacéutico en la farmacia de comunidad para mejorar la
adherencia a los medicamentos en los nuevos usuarios de estatinas.
Sesiones de consejería frecuentes (cada 3 meses) son necesarios para
mantener los efectos positivos de la descontinuación. Aunque las mejorías
son modesta, el programa puede ser fácilmente aplicado a una población
más grande y tener un gran impacto; y las intervenciones son relativamente
pocos costosas y fáciles de implementar en la práctica clínica. 
Traducido por Wilma M. Guzmán-Santos
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RÉSUMÉ
OBJECTIF: Mettre en place et évaluer l’efficacité d’un programme de
soins pharmaceutiques en officine pour améliorer l’adhésion des patients
à la prise des statines.
MÉTHODES: Une étude ouverte, prospective, randomisée a été effectuée
dans 26 officines aux Pays-Bas. Les nouveaux utilisateurs de statines
âgées de plus de 18 ans ont été répartis au hasard pour recevoir des soins
usuels ou l’intervention d’un pharmacien. Les interventions consistaient
en 5 sessions individuelles de conseils aux patients effectuées par le
pharmacien durant une période d’une année. Au cours de ces sessions,
les patients ont reçu de l’information structurée concernant l’importance
de prendre ses médicaments, les cibles visées de cholestérol et
l’association entre l’adhésion et les niveaux de cholestérol. L’adhésion à
la prise des statines a été mesurée selon le taux d’arrêt à 6 et 12 mois
suite à la phase d’initiation de la statine et le ratio de possession de
médicaments.
RÉSULTATS: Un nombre de 899 patients (439 dans le groupe soins pharma-
ceutiques et 460 dans le groupe soins usuels) a été évalué. Le programme
de soins pharmaceutiques a eu un taux d’arrêt significativement plus bas
en dedans de 6 mois du début du traitement (HR 0.66; 95% CI 0.46-
0.96). Aucune différence significative entre les 2 groupes n’a été
observée dans l’arrêt du traitement à 12 mois (HR 0.84; 95% CI 0.65-
1.10). Le ratio de possession de médicament était très élevé (>99%) dans
les 2 groupes soit pour le groupe de soins pharmaceutiques et pour le
groupe de soins usuels et il n’y avait pas de différence entre les 2 groupes. 
CONCLUSIONS: Les auteurs ont démontré la faisabilité et l’efficacité d’un
programme de soins pharmaceutiques pour améliorer l’adhésion chez
des nouveaux utilisateurs de statines. Des sessions d’information
régulières (aux 3 mois) sont nécessaires pour maintenir les effets positifs.
Même si les améliorations sont modestes, le programme peut être
facilement mis en place et avoir des impacts importants puisque les
interventions ne sont pas dispendieuses et facilement mises en place.
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